Key Takeaways
- • Aqua Medical closed a Series B financing round led by Nashville-based Relevance Ventures to advance its investigational Proximal Intestinal Mucosal Ablation (PIMA) procedure for Type 2 diabetes treatment.
- • Proceeds will fund completion of the ongoing U.S. RESTORE-1 pilot study and operational preparations for a planned U.S. pivotal trial, contingent on regulatory authorization.
- • The company's proprietary radiofrequency vapor ablation (RFVA) system is FDA-cleared for general gastrointestinal use, though its application for PIMA remains investigational with safety and efficacy not yet established.
- • Aqua Medical's technology represents a minimally invasive, device-based approach delivered through the working channel of an endoscope, targeting metabolic mechanisms associated with Type 2 diabetes.
Summary
Aqua Medical, a clinical-stage medical technology company based in Pleasanton, California, has announced the completion of a Series B financing round led by Relevance Ventures, a Nashville-based investment firm. The financing will support critical milestones in the company's clinical development pipeline for treating Type 2 diabetes through an investigational endoscopic procedure.
The capital raised will be deployed toward two primary objectives: completing Aqua Medical's ongoing U.S. RESTORE-1 pilot study and funding operational infrastructure necessary to initiate a planned U.S. pivotal trial evaluating the company's Proximal Intestinal Mucosal Ablation (PIMA) procedure. Advancement to the pivotal trial phase remains subject to regulatory authorization from the FDA.
Aqua Medical's core technology centers on a proprietary radiofrequency vapor ablation (RFVA) system designed as a minimally invasive intervention delivered through the working channel of an endoscope. The platform targets pathophysiological mechanisms underlying Type 2 diabetes with the objective of delivering metabolic improvements through a scalable, device-based approach. The RFVA system has received FDA marketing clearance for general use in gastrointestinal applications, though its specific deployment for the PIMA procedure remains investigational. The company emphasizes that safety and efficacy of the RFVA system for PIMA have not yet been established, underscoring the investigational status of this indication.
This financing round positions Aqua Medical to advance from pilot-stage validation into pivotal trial execution, a critical inflection point for medical device companies seeking regulatory approval and eventual commercialization in the Type 2 diabetes treatment market.
The capital raised will be deployed toward two primary objectives: completing Aqua Medical's ongoing U.S. RESTORE-1 pilot study and funding operational infrastructure necessary to initiate a planned U.S. pivotal trial evaluating the company's Proximal Intestinal Mucosal Ablation (PIMA) procedure. Advancement to the pivotal trial phase remains subject to regulatory authorization from the FDA.
Aqua Medical's core technology centers on a proprietary radiofrequency vapor ablation (RFVA) system designed as a minimally invasive intervention delivered through the working channel of an endoscope. The platform targets pathophysiological mechanisms underlying Type 2 diabetes with the objective of delivering metabolic improvements through a scalable, device-based approach. The RFVA system has received FDA marketing clearance for general use in gastrointestinal applications, though its specific deployment for the PIMA procedure remains investigational. The company emphasizes that safety and efficacy of the RFVA system for PIMA have not yet been established, underscoring the investigational status of this indication.
This financing round positions Aqua Medical to advance from pilot-stage validation into pivotal trial execution, a critical inflection point for medical device companies seeking regulatory approval and eventual commercialization in the Type 2 diabetes treatment market.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.